Fredrik Björck1, Henrik Renlund2, Gregory Y H Lip3, Per Wester4, Peter J Svensson5, Anders Själander1. 1. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. 2. Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden. 3. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, England4Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 4. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden5Department of Clinical Sciences, Danderyds Hospital, Karolinska Institute, Stockholm, Sweden. 5. Department for Coagulation Disorders, University of Lund, Malmö, Sweden.
Abstract
IMPORTANCE: Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). NOAC studies were based on comparisons with warfarin arms with times in therapeutic range (TTRs) of 55.2% to 64.9%, making the results less credible in health care systems with higher TTRs. OBJECTIVES: To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control. DESIGN, SETTING, AND PARTICIPANTS: A retrospective, multicenter cohort study based on Swedish registries, especially AuriculA, a quality register for AF and oral anticoagulation, was conducted. The register contains nationwide data, including that from specialized anticoagulation clinics and primary health care centers. A total of 40 449 patients starting warfarin therapy owing to nonvalvular AF during the study period were monitored until treatment cessation, death, or the end of the study. The study was conducted from January 1, 2006, to December 31, 2011, and data were analyzed between February 1 and November 15, 2015. Associating complications with risk factors and individual INR control, we evaluated the efficacy and safety of warfarin treatment in patients with concomitant aspirin therapy and those with no additional antiplatelet medications. EXPOSURES: Use of warfarin with and without concomitant therapy with aspirin. MAIN OUTCOMES AND MEASURES: Annual incidence of complications in association with individual TTR (iTTR), INR variability, and aspirin use and identification of factors indicating the probability of intracranial bleeding. RESULTS: Of the 40 449 patients included in the study, 16 201 (40.0%) were women; mean (SD) age of the cohort was 72.5 (10.1) years, and the mean CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age ≥75 years [doubled], diabetes mellitus, stroke [doubled]-vascular disease, age 65-74 years, and sex category [female]) score was 3.3 at baseline. The annual incidence, reported as percentage (95% CI) of all-cause mortality was 2.19% (2.07-2.31) and, for intracranial bleeding, 0.44% (0.39-0.49). Patients receiving concomitant aspirin had annual rates of any major bleeding of 3.07% (2.70-3.44) and thromboembolism of 4.90% (4.43-5.37), and those with renal failure were at higher risk of intracranial bleeding (hazard ratio, 2.25; 95% CI, 1.32-3.82). Annual rates of any major bleeding and any thromboembolism in iTTR less than 70% were 3.81% (3.51-4.11) and 4.41% (4.09-4.73), respectively, and, in high INR variability, were 3.04% (2.85-3.24) and 3.48% (3.27-3.69), respectively. For patients with iTTR 70% or greater, the level of INR variability did not alter event rates. CONCLUSIONS AND RELEVANCE: Well-managed warfarin therapy is associated with a low risk of complications and is still a valid alternative for prophylaxis of AF-associated stroke. Therapy should be closely monitored for patients with renal failure, concomitant aspirin use, and poor INR control.
IMPORTANCE: Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). NOAC studies were based on comparisons with warfarin arms with times in therapeutic range (TTRs) of 55.2% to 64.9%, making the results less credible in health care systems with higher TTRs. OBJECTIVES: To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control. DESIGN, SETTING, AND PARTICIPANTS: A retrospective, multicenter cohort study based on Swedish registries, especially AuriculA, a quality register for AF and oral anticoagulation, was conducted. The register contains nationwide data, including that from specialized anticoagulation clinics and primary health care centers. A total of 40 449 patients starting warfarin therapy owing to nonvalvular AF during the study period were monitored until treatment cessation, death, or the end of the study. The study was conducted from January 1, 2006, to December 31, 2011, and data were analyzed between February 1 and November 15, 2015. Associating complications with risk factors and individual INR control, we evaluated the efficacy and safety of warfarin treatment in patients with concomitant aspirin therapy and those with no additional antiplatelet medications. EXPOSURES: Use of warfarin with and without concomitant therapy with aspirin. MAIN OUTCOMES AND MEASURES: Annual incidence of complications in association with individual TTR (iTTR), INR variability, and aspirin use and identification of factors indicating the probability of intracranial bleeding. RESULTS: Of the 40 449 patients included in the study, 16 201 (40.0%) were women; mean (SD) age of the cohort was 72.5 (10.1) years, and the mean CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age ≥75 years [doubled], diabetes mellitus, stroke [doubled]-vascular disease, age 65-74 years, and sex category [female]) score was 3.3 at baseline. The annual incidence, reported as percentage (95% CI) of all-cause mortality was 2.19% (2.07-2.31) and, for intracranial bleeding, 0.44% (0.39-0.49). Patients receiving concomitant aspirin had annual rates of any major bleeding of 3.07% (2.70-3.44) and thromboembolism of 4.90% (4.43-5.37), and those with renal failure were at higher risk of intracranial bleeding (hazard ratio, 2.25; 95% CI, 1.32-3.82). Annual rates of any major bleeding and any thromboembolism in iTTR less than 70% were 3.81% (3.51-4.11) and 4.41% (4.09-4.73), respectively, and, in high INR variability, were 3.04% (2.85-3.24) and 3.48% (3.27-3.69), respectively. For patients with iTTR 70% or greater, the level of INR variability did not alter event rates. CONCLUSIONS AND RELEVANCE: Well-managed warfarin therapy is associated with a low risk of complications and is still a valid alternative for prophylaxis of AF-associated stroke. Therapy should be closely monitored for patients with renal failure, concomitant aspirin use, and poor INR control.
Authors: Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson Journal: J Thromb Thrombolysis Date: 2017-05 Impact factor: 2.300
Authors: Sean D Pokorney; DaJuanicia N Holmes; Laine Thomas; Gregg C Fonarow; Peter R Kowey; James A Reiffel; Daniel E Singer; James V Freeman; Bernard J Gersh; Kenneth W Mahaffey; Elaine M Hylek; Gerald V Naccarelli; Michael D Ezekowitz; Jonathan P Piccini; Eric D Peterson Journal: JAMA Cardiol Date: 2019-08-01 Impact factor: 14.676
Authors: Mauro Molteni; Mario Bo; Giovanni Di Minno; Giuseppe Di Pasquale; Simonetta Genovesi; Danilo Toni; Paolo Verdecchia Journal: Intern Emerg Med Date: 2017-04-24 Impact factor: 3.397
Authors: Mariam Ujeyl; Ingrid Köster; Hans Wille; Thomas Stammschulte; Rebecca Hein; Sebastian Harder; Ursula Gundert-Remy; Julian Bleek; Peter Ihle; Helmut Schröder; Gerhard Schillinger; Anette Zawinell; Ingrid Schubert Journal: Eur J Clin Pharmacol Date: 2018-06-16 Impact factor: 2.953
Authors: Sylvia Haas; Hugo Ten Cate; Gabriele Accetta; Pantep Angchaisuksiri; Jean-Pierre Bassand; A John Camm; Ramon Corbalan; Harald Darius; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Barry Jacobson; Gloria Kayani; Lorenzo G Mantovani; Frank Misselwitz; Karen Pieper; Sebastian M Schellong; Janina Stepinska; Alexander G G Turpie; Martin van Eickels; Ajay K Kakkar Journal: PLoS One Date: 2016-10-28 Impact factor: 3.240
Authors: Heidi Lehtola; Antti Palomäki; Pirjo Mustonen; Päivi Hartikainen; Tuomas Kiviniemi; Henri Sallinen; Ilpo Nuotio; Antti Ylitalo; K E Juhani Airaksinen; Juha Hartikainen Journal: Neurol Clin Pract Date: 2018-08